Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study

Hans Christian Kolberg, Marco Colleoni, Georgia Savva Demetriou, Patricia Santi, Hans Tesch, Yasuhiro Fujiwara, Zorica Tomasevic, Vladimir Hanes

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds